β-Arrestin1 Mediates the Endocytosis and Functions of Macrophage Migration Inhibitory Factor by Xie, Lishi et al.
b-Arrestin1 Mediates the Endocytosis and Functions of
Macrophage Migration Inhibitory Factor
Lishi Xie
1,2., Xiaohang Qiao
1,2., Yanfang Wu
1, Jie Tang
1*
1Center for Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, People’s Republic of China, 2Graduate University, Chinese Academy of
Sciences, Beijing, People’s Republic of China
Abstract
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine, regulating inflammatory and immune responses. MIF
binds to cell surface receptor CD74, resulting in both rapid and sustained ERK activation. It was reported that MIF-induced
rapid ERK activation requires its co-receptor CD44. But the exact mechanism underlying sustained ERK activation is not well
understood. In the current study, we described a detailed mechanism of MIF mediated sustained ERK activation. We found
that b-arrestin1, a scaffold protein involved in the activation of the MAPK cascade, interacts with CD74 upon MIF
stimulation, resulting in CD74-mediated MIF endocytosis in a chlorpromazine (CPZ)-sensitive manner. b-arrestin1 is also
involved in endocytotic MIF signaling, leading to sustained ERK activation. Therefore b-arrestin1 plays a central role in
coupling MIF endocytosis to sustained ERK activation.
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Introduction
Macrophage migration inhibitory factor (MIF) is a ubiquitously
expressed pleiotropic cytokine that functions as a pro-inflammatory
mediator. MIF is involved in the pathogenesis of many inflamma-
tory diseases and cancer development [1]. The molecular
mechanism of MIF’s action appears to be unique among
proinflammatory cytokines. MIF induces a rapid and transient
ERK activation (lasts less than 90 minutes) [2], as well as a sustained
ERK activation (lasts up to 24 hours) [3]. It was reported that MIF-
induced rapid ERK activation is mediated by CD74 and CD44
receptor complex. CD74 is responsible for MIF cell surface binding,
and CD44 is necessary for MIF signal transduction [4]. However,
the molecular mechanism underlying the sustained ERK activation
induced by MIF is not clear yet. Besides CD44 and CD74, MIF has
another two cell surface receptors, chemokine receptor CXCR2
and CXCR4, which are involved in MIF-mediated migratory
function [5]. Although it has been reported that MIF can be taken
up by both immune and non-immune cells in a temperature and
energy dependent manner [6,7], the detailed mechanism and
function of the endocytosis of MIF remain unclear.
b-arrestin is a versatile adaptor well known for its role in G
protein-coupled receptor (GPCR) desensitization, internalization
and signal transduction [8]. New evidences indicated that b-
arrestin is also a signaling molecule in single transmembrane
receptor pathways, such as the IGF-1 receptor and TGF-b
receptor signal pathways [9]. One of the well characterized b-
arrestin signaling pathways is b-arrestin-dependent activation of
the ERK/MAPK pathway. b-arrestin works as a scaffold protein
to recruit Raf, MEK and ERK to the receptor, enhancing
activation of ERK [10]. This protein complex remains attached to
the receptor as it travels to the early endosome, thus promoting
sustained MAPK signaling [11]. Given the similarity between b-
arrestin and MIF in endocytosis and sustained ERK phosphor-
ylation, we hypothesize that b-arrestin may also play a role in MIF
endocytosis and subsequent signaling events.
In the current study, we demonstrated that MIF undergoes a
chlorpromazine (CPZ)-sensitive endocytosis in the mouse macro-
phage cell line RAW264.7, and it is CD74-dependent. Upon MIF
stimulation, b-arrestin1 interacts with the endocytic CD74. As an
adaptor, b-arrestin1 recruits downstream signal molecules,
resulting in sustained ERK activation and cell cycle progress.
Therefore we described a detailed mechanism linking CD74-
mediated MIF endocytosis with sustained ERK activation and
defined a central role of b-arrestin in this process.
Results
Cellular uptake of MIF by chlorpromazine-sensitive
endocytosis
Previous biochemical studies have shown that the uptake of
MIF is temperature and energy dependent [7], but the precise
mechanism of MIF internalization remains unclear. RAW264.7
was incubated with tetramethyl rhodamine labeled biologically
active MIF (MIF-TRITC) to visualize the internalization of MIF
by using confocal laser scanning microscopy. At 4uC, which is a
condition nonpermissive for internalization, MIF-TRITC was
only detected on the cell surface (Fig. S1A). Subsequently cells
were washed extensively to remove non-specific binding MIF and
recovered at 37uC for a few minutes. MIF-TRITC could be
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endosomes/lysosomes afterwards (Fig. 1A). Increased intracellular
accumulation of MIF-TRITC containing endocytic vesicles was
observed with longer incubation time (Fig. S1A).
Endocytosis in vertebrate cells occurs by two main mechanisms:
clathrin-dependent and clathrin-independent endocytosis. The
latter is also known as lipid-raft-dependent endocytosis [12].
Clathrin-dependent endocytosis can be blocked by chlorproma-
zine (CPZ), which leads to adaptor protein complex 2 (AP2) and
clathrins redistributed away from the plasma membrane [13]. On
the other hand, most clathrin-independent endocytosis can be
inhibited by sequestering cellular cholesterol with Filipin [14]. To
investigate the mechanism of MIF endocytosis, RAW264.7 cells
were pre-treated with CPZ or Filipin for 30 minutes, and then
incubated with MIF-TRITC for 2 hours at 37uC. Blocking the
clathrin-independent pathway by Filipin had no effect on the
endocytosis of MIF-TRITC. However, inhibition of the clathrin-
dependent pathway by CPZ abolished the endocytosis of MIF-
TRITC and arrested MIF-TRITC at the cell surface (Fig. 1B).
Same results of the temperature and clathrin dependent endocytosis
of MIF-TRITC were also observed by flow cytometry, a semi-
quantitative analysis method. At 4uC, the endocytosis of MIF-TRITC
was much lower than that at 37uC (Fig. 1C). Furthermore the
endocytosis of MIF-TRITC could be antagonized by 10-fold excess of
unlabeled MIF, suggesting that this process is receptor dependent.
Finally, the endocytosis of MIF-TRITC can be efficiently suppressed
by clathrin-dependent endocytosis inhibitor, CPZ (Fig. 1C).
The endocytosis of MIF contributes to sustained ERK
activation
Endocytosis and cell-surface receptor recycling are crucial for
the magnitude, duration and nature of signaling cascade [12]. To
Figure 1. Uptake of MIF via chlorpromazine (CPZ)-sensitive endocytosis. A, Uptake of MIF in RAW264.7 cells. RAW264.7 cells were
incubated with MIF-TRITC for 1 h at 37uC, and then stained with LysoTraker Green and Hoechst. Subcellular distribution of MIF-TRITC was imaged
with confocal microscopy. B, Uptake of MIF-TRITC is clathrin-dependent. RAWRAW264.7 cells were pretreated with Filipin (5 mM) or CPZ (5 mg/ml) for
30 min before stimulation with MIF-TRITC for another 2 h. Staining and confocal microscopy was carried out as in A. C, Uptake of MIF-TRITC is
specific and temperature dependent. RAWRAW264.7 cells were treated with MIF-TRITC under the conditions indicated. MIF endocytosis was
measured by FACS and the geometric mean of fluorescent signals was calculated by normalizing the signal of each sample with the signal of
untreated cells. The experiment was repeated three times and means 6 S.D. are indicated. *: Statistical analysis was carried out using the Student’s t-
test and P,0.05 was considered statistically significant. D, The sustained ERK activation induced by MIF is endocytosis-dependent. Serum-starved
RAW264.7 cells were treated with CPZ for 30 min before stimulation with MIF for 15 min or 240 min. Western blot analysis was carried out using anti-
ERK and anti-pERK antibodies. Scale bars: 10 mm.
doi:10.1371/journal.pone.0016428.g001
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a representative signaling event upon MIF stimulation [3], we
investigated the rapid and sustained ERK phosphorylation after
MIF stimulation. In RAW264.7 cells, ERK activation was
detectable 10 min after MIF treatment and lasted more than
12 hours. The peak of ERK activation appeared from 60 to
240 min, which is consistent with the time frame of MIF
endocytosis (Fig. S1B). In addition, sustained ERK activation
(240 min) induced by MIF can be attenuated by CPZ pretreat-
ment. In contrast, the rapid ERK activation (15 min) induced by
MIF was not inhibited, but rather was slightly elevated (Fig. 1D).
This elevated rapid ERK activation may be explained by longer
sequestration of MIF on the cell surface after CPZ treatment.
CD74 is involved in the endocytosis of MIF
The likely involvement of clathrin in the endocytosis of MIF and
the association of endocytosis with sustained ERK activation
prompted us to investigate the role of MIF receptors in this
process. The first identified MIF cell surface receptor, CD74, is a
type II transmembrane receptor that constantly recycles between
the cell surface and the cytosol [6]. Recent studies have found that
depletion of clathrin or AP-2 results in increased CD74 expression
on the cell surface [15]. In addition, as the cell surface receptor of
MIF, CD74 contributes to MIF-induced ERK activation [6].
To test whether CD74 plays a role in MIF endocytosis, we used
an N-terminal GFP-fused CD74 to follow its dynamic within the
cell after MIF stimulation. GFP-CD74 or GFP plasmid was
transiently transfected into COS-7 cells which are CD74 deficient
[6] and MIF-TRITC was added to the cells 36 hours after
transfection. While MIF cannot be taken up by GFP transfected
cells (data not shown), it can be internalized by GFP-CD74
transfected cells. Before MIF stimulation, GFP-CD74 was evenly
distributed in the cytosol and cell surface. However, GFP-CD74
became co-localized with MIF-TRITC in endosomes after
60 min’s incubation (Fig. 2A). Similar results were observed in
RAW264.7 cells (Fig. S2A), suggesting that MIF was internalized
via a CD74-mediated pathway.
Using similar strategy, we investigated whether other MIF
receptors were involved in the endocytosis of MIF. CD44-GFP
and CXCR4-GFP did not co-localize with MIF-TRITC in
RAW264.7 cells upon stimulation, whereas CXCR2-GFP partially
co-localized with MIF-TRITC (Fig. S2B). Moreover, the endog-
enous CD74 was also found co-localized with MIF-TRITC in
RAW264.7 cells by immunofluorescence (Fig. 2B). But the
endogenous staining of CD44 didn’t show co-localization with
MIF-TRITC (data not shown). To confirm that CD74 is required
for MIF endocytosis, we knocked down CD74 expression in
RAW264.7 cells by RNA interference (Fig. S3A). Flow cytometry
Figure 2. CD74 contributes to MIF endocytosis. A, CD74 co-localizes with internalized MIF in COS-7 cells. COS-7 cells were transiently
transfected with GFP-CD74, and stimulated with (bottom) or without (upper) MIF-TRITC for 1 h. MIF-TRITC and GFP-CD74 localization was imaged
with confocal microscopy. B, Internalized MIF-TRITC co-localizes with endogenous CD74. Serum-starved RAW264.7 cells were stimulated with MIF-
TRITC for 1 h. Permeablized cells were labeled with anti-CD74-FITC antibody and imaged with confocal microscopy. C, MIF endocytosis is CD74-
dependent. CD74 specific shRNA (shCD74) or non-specific shRNA (shNS) stably transfected RAW264.7 cells were incubated with MIF-TRITC and
analyzed with FACS. Scale bars: 10 mm.
doi:10.1371/journal.pone.0016428.g002
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as a result of CD74 depletion (Fig. 2C). Thus, CD74 is required for
MIF endocytosis.
b-arrestin1 is required for the endocytosis of MIF and
subsequent sustained ERK activation
b-arrestin exists as two isoforms, b-arrestin1 and b-arrestin2,
both of which are important in the regulation of GPCR
desensitization, internalization and signaling events. Recent
evidences suggested that b-arrestin can also regulate the
endocytosis and signaling of non-GPCR receptors [9].
To test whether b-arrestin is involved in the endocytosis of MIF,
we followed the localization of b-arrestin before and after MIF-
TRITC incubation. In stable b-arrestin1-GFP expressing
RAW264.7 cells, b-arrestin1-GFP evenly distributed in the
cytosol. Upon MIF-TRITC stimulation b-arrestin-GFP accumu-
lated into some vesicles and co-localized with MIF-TRITC
bearing vesicles (Fig. 3A). Similar results were observed in COS-
7 cells. b-arrestin1-GFP or b-arrestin2-GFP constructs were
transiently co-transfected with CD74-myc in COS-7 cells and
MIF-TRITC uptake was examined 36 hours after transfection.
Only b-arrestin1-GFP and MIF-TRITC were found co-localized
in endosomes after stimulation (Fig. S4A). To confirm that b-
arrestin1 contributes to MIF endocytosis, we knocked down b-
arrestin1 in RAW264.7 cells by RNA interference (Fig. S3B).
MIF-TRITC uptake was significantly reduced as a result of b-
arrestin1 depletion (Fig. 3B).
As a scaffold protein for endocytosis and signaling in GPCR, b-
arrestin associates with specific components of the MAPK cascade
[10]. To investigate the role of b-arrestin1 in MIF-induced ERK
activation, we tested the ability of MIF to induce ERK activation
after b-arrestin1 depletion in RAW264.7 cells. MIF-induced
sustained ERK activation was impaired in b-arrestin1 shRNA
transfected RAW264.7 cells compared to non-specific shRNA
transfected cells. However, there was no significant difference in
rapid ERK activation upon MIF treatment (Fig. 3C).
COS-7 cells express very low level of endogenous b-arrestin
[16], and MIF-induced sustained ERK activation was not
observed in COS-7 cells, even with CD74 over-expression [4].
To test whether b-arrestin1 can rescue MIF-induced sustained
ERK activation in COS-7 cells, we co-expressed b-arrestin1 and
CD74 transiently in COS-7 cells. Upon MIF stimulation,
sustained ERK activation was observed in co-transfected cells,
but not in cells expressing only b-arrestin1 or CD74 (Fig. 3D). To
investigate in more detail how b-arrestin1 affects sustained ERK
activation after MIF stimulation, two b-arrestin1 mutants were
introduced. b-arrestin1 S412D mutant cannot target receptors to
clathrin-coated pits, thus disturbs b-arrestin1 mediated receptor
endocytosis. b-arrestin1 (P91G-P121E) mutant (A1src), with the c-
Src binding site disrupted, is defective in ERK activation, but not
in b-arrestin1-mediated endocytosis [17]. MIF-induced sustained
ERK activation was not observed when S412D or A1src mutant
was co-expressed with CD74 in COS-7 cells (Fig. 3E). Our results
suggest that b-arrestin1 serves as an important adaptor for MIF
endocytosis and subsequent signal transduction by providing a
scaffold for clathrin, c-Src and components of MAPK cascade.
Sustained ERK activation is required for cell cycle progression
through G1 phase [18]. Inhibition of ERK activation causes cells
to be arrested at the G1 phase [19]. In addition, it was reported
that sustained ERK activation and related cell cycle progression in
the IGF-1 receptor pathway is mediated by b-arrestin1 [9]. Since
we have demonstrated that b-arrestin1 is involved in MIF-initiated
sustained ERK activation, we further investigated the role of b-
arrestin1 in MIF-induced cell cycle progression. As shown in
Fig. 3F, MIF induced cell cycle progression was inhibited by b-
arrestin1 knockdown in RAW264.7 cells, compared to mock cells,
whilst in non-stimulated cells, b-arrestin1 knockdown did not
affect the cell cycle.
b-arrestin1 binds to CD74 and links MIF endocytosis to
sustained ERK activation
b-arrestin bridges ERK activation with the endocytosis of the
corresponding receptors. b-arrestin recruits downstream signaling
molecules to the clathrin-coated pits that contain receptors. Along
with these signaling complexes, b-arrestins internalizes with
receptor containing endocytic vesicles to prolong the signal
activation [20]. We observed that b-arrestin1 co-localized with
internalized MIF-TRITC, and CD74 was also present in MIF
containing vesicles in COS-7 and RAW264.7 cells. It suggests that
b-arrestin1 may link MIF endocytosis to sustained ERK activation
by interacting with CD74 directly.
Results from confocal microscopy showed that upon MIF
stimulation b-arrestin1 translocated from cytosol to plasma
membrane and later ended up in the same vesicles along with
CD74 (Fig. 4A). Further investigation showed that b-arrestin1
interacts with CD74 in reciprocal co-immunoprecipitation exper-
iments (Fig. 4B), and this interaction is MIF-dependent (Fig. S4B).
Discussion
The results presented here suggested a novel mechanism
underlining MIF induced sustained ERK activation. Upon MIF
stimulation, b-arrestin1 binds to CD74, triggers MIF and CD74
complex internalization, and serves as a scaffold for recruiting
downstream signal molecules, such as components of the MAPK/
ERK cascade. Subsequently, MIF endocytic vesicles entry into
cytosol along with the b-arrestin1 scaffolds. By stabilizing Raf/
MEK/ERK complex, b-arrestin1 maintains MIF-induced ERK
activation for a comparatively long period of time (Fig. 4C).
MIF was one of the first cytokines discovered [21]. An
important feature of MIF signaling is its ability to induce both
rapid and sustained ERK activation [2,3]. Via this pathway MIF
regulates cell proliferation [3] and adhesion-dependent signaling
responses [22]. MIF signaling is known to induce a rapid ERK
activation through a receptor complex comprising CD74 and
CD44 [4], which is depends on Jab1, a intracellular binding
partner of MIF, and Src kinase activity[2].The sustained ERK
activation induced by MIF was suggested to be mediated by
autocrine MIF, and Rho GTPase, MLCK activation may be
involved in this process [3,23], while Jab1 inhibits the sustained
ERK activation likely by blocking MIF secretion[2,24]. However,
since intracellular MIF also binds to and activates MLCK [25] and
extracellular MIF is efficiently endocytosed and translocated into
the cytosol, it is possible that the autocrine action of extracellular
MIF in sustained ERK signalling involves MIF endocytosis. We
found that reduction of MIF uptake was followed by attenuation of
sustained ERK activation after CPZ pretreatment, which
suggested the association and consecution between MIF endocy-
tosis and its sustained ERK activation.
Previous biochemical studies have shown that the uptake of
MIF is temperature and energy dependent [7], presented confocal
and flow cytometry results showed that it was a CPZ sensitive
process, these evidences suggests that the endocytosis of MIF may
be a clathrin-dependent pathway, while because of the limitation
of the chemical inhibitors, exact pathway cannot be determined at
the present time.It was reported that MIF-induced sustained ERK
activation was proposed to occur through a receptor-mediated
signaling pathway [2]. Our confocal microscopy results showed
b-Arrestin1 and MIF Endocytosis and Signaling
PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e16428Figure 3. b-arrestin1 is involved in MIF endocytosis and sustained ERK activation. A, b-arrestin1 is co-localized with MIF in RAW264.7 cells.
RAW264.7 cells expressing ARRB1-GFP were either unstimulated (top) or stimulated (bottom) with MIF-TRITC for 1 h and subsequently fixed. Cellular
distribution of b-arrestin1 and MIF-TRITC was imaged by confocal microscopy. Scale bars: 5 mm B, MIF endocytosis is b-arrestin1-dependent. b-
arrestin1 knocked-down RAW264.7 cells (shARRB1) were stimulated with MIF-TRITC and analyzed with FACS. C–E, b-arrestin1 is involved in sustained
ERK activation induced by MIF. C, RAW264.7 cells stably transfected with a b-arrestin1-specific (shARRB1) and non-specific shRNA (shNS) plasmid were
stimulated with MIF (200 ng/ml) for 10 min or 150 min. Cell extracts were subjected to Western blotting with anti-pERK and anti-ERK antibodies. D,E
Same as C, except COS-7 cells were transiently co-transfected with plasmids as indicated. Serum-starved cells were stimulated with MIF (200 ng/ml)
for 10 min or 150 min, and F, b-arrestin1 is important for the cell cycle progress induced by MIF. RAW264.7 cells stably transfected with shARRB1 or
shNS were stimulated with MIF (200 ng/ml) for 12 h and stained with propidium iodide. The samples were then subjected to FACS analysis and the
percentages of cells in the G1 and S phases were calculated. The experiment was repeated three times and the results are shown as means 6 S.D. *
Statistical analysis was carried out using the Student’s t-test and P,0.05 was considered statistically significant. ARRB1, b-arrestin1; S412D, b-arrestin1
mutant; A1Src, b-arrestin mutant.
doi:10.1371/journal.pone.0016428.g003
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CD74 and endogenous CD74. Depletion of CD74 not only
repressed the endocytosis of MIF, but also inhibited MIF-induced
sustained ERK activation. These all suggested that the endocytosis
of MIF and downstream sustained ERK activation are both
mediated by receptor, CD74. We also studied the roles of other
three cell surface receptors of MIF in this process. The
endocytosed MIF didn’t co-localize with GFP-tagged CD44 and
CXCR4, which were ruled out firstly. Correspondingly, endocy-
tosed MIF partially co-localized with GFP-tagged CXCR2. It was
recently reported that CD74 interacts with CXCR2 [5] or
CXCR4 leading to alternative signaling pathways such as Akt
activation [26]. Those signal transduction pathways may share
similar mechanism that using b-arrestins as mediators [27]. Those
alternative pathways may be the subject for future studies.
b-arrestin1 is an adaptor protein for GPCR, as well as non-
GPCR, and it can mediate receptor internalization and signaling
to the mitogen-activate protein kinases ERK, JNK, and p38 as
well as Akt, PI3K, and RhoA [8]. In this study, we found that b-
arrestin1 interacted with CD74 upon MIF stimulation and played
a central role in coupling MIF endocytosis with downstream
signaling. Src phosphorylation is a necessary step in the activation
of various mitogenic signaling pathways including the MAPK/
ERK pathway. It has been reported that c-Src is required for MIF
induced rapid ERK activation [2,4], but the Src binding site in the
intracellular domain of CD74 is not clear. Here we found that
MIF dependent sustained ERK activation is significantly attenu-
ated when b-arrestin1 mutant A1src (deficient in c-Src binding)
was introduced. Thus our work also explained how Src
recruitment by b-arrestin1 connects with MIF-induced sustained
ERK activation.
MIF plays important role in maintenance of steady state Cyclin
D1 expression and cell proliferation in immortalized rodent
fibroblasts through a number of signaling elements, including
ERK activation [23]. Importantly, Cyclin D1 expression is not
activated by transient ERK signalling but is only triggered after
sustained activation of this pathway [28,29,30]. Our data links
CD74-mediated MIF endocytosis and downstream signal trans-
duction in the context of cell cycle progression. It has been
reported that MIF expression is correlated with cancer prognosis,
specifically for hepatocellular carcinomas, colon cancers and
prostate cancers [31,32,33]. MIF may indirectly facilitate tumor
growth via promotion of angiogenic response [34,35]. Our result
also suggests a new way by which MIF may contribute to
tumorigenesis: facilitating cell cycle progression and proliferation
through b-arrestin1 mediated sustained ERK activation. The
linkage between ERK activation and cell cycle progression
induced by MIF can also shed light on inflammatory diseases in
terms of persistence of inflammatory cells or growth of intrinsic
cells. It has been reported that antigen-induced arthritis is reduced
in MIF deficient mice, which is associated with reduction of
splenocyte proliferation and T cell activation dependent on ERK
activation [36].
This is the first study that defines a role for b-arrestin1 in the
endocytosis of MIF and the downstream signaling events,
providing an important link in the biology of MIF. Cellular signal
transduction involves highly coordinated cascades of events. Our
results showed that MIF employs b-arrestin1 as a molecular
scaffold to maintain integrity and specificity of signaling.
Understanding molecular mechanism of MIF-induced sustained
ERK activation is imperative for both basic research and practical
applications, and it will help us to find new ways to treat related
diseases by fine tuning of this pathway.
Materials and Methods
Cell Culture
COS-7 and RAW264.7 cells (both from ATCC) were cultured
in Dulbecco’s modified Eagle’s medium plus 10% (v/v) heat-
inactivated fetal bovine serum. All cell culture was carried out at
37uC in a humidified incubator with 5% CO2. Plasmids were
transiently transfected into the cells using Lipofectamine 2000
(Invitrogen). Plasmid constructs and sequences of oligo used are
listed in the supporting information.
Antibodies and reagents
p-ERK, ERK-1, Myc, tubulin and actin specific antibodies were
purchased from Santa Cruz Biotechnology. ARRB1/2 (A1CT)
antibody was kindly provided by Dr. Lefkowitz. Chlorpromazine
(CPZ) and the nuclear dye Hoechst 33342 were purchased from
Sigma-Aldrich. The lysosome dye, LysoTrackerH Green DND-26
(L7526) was purchased from Molecular Probes
TM.
Plasmid constructs
The pCI-EGFP plasmid (GFP fused to the C terminus of the
targeted protein) was generated by inserting the EGFP coding
sequence into Sal I and Not I sites of the pCI-neo vector
(Promega). ARRB1-GFP and GFP-CD74 were constructed by
subcloning a full-length human b-arrestin1 cDNA and CD74
cDNA into the EcoRI and Sal I sites of pCI-EGFP. Myc-tagged
ARRB1 and CD74 were generated by subcloning a full-length b-
arrestin1 cDNA and a CD74 cDNA fragment into the pCI-neo
vector containing the coding sequence of the Myc epitope. The b-
arrestin1 mutant A1src was kindly provided by Dr. Lefkowitz.
shRNAs against murine b-arrestin1 and CD74 was obtained by
cloning the target sequence into pSUPER (Oligoengine Inc.,
Seattle, WA, USA) RNAi vector. The oligonucleotides used in this
study are indicated in Supplementary Information (Table S1).
MIF stimulation
Recombinant human MIF was purified from an expression
system as previously described [37] and contaminating endotoxin
is inactivated by Polymyxin B [38]. MIF is labeled with TRITC
(Sigma-Aldrich) as described before [39]. For ERK activation
studies, RAW264.7 cells were plated at a density of 4610
5 cells/ml
and allowed to grow for 12 h in high glucose DMEM with 10%
FBS. The cells were starved in DMEM with 0.1% (v/v) FBS for
12 h. Without a medium change, the cells were treated with 5 mg/
ml CPZ (Sigma-Aldrich) for 30 min, recombinant MIF was added
Figure 4. b-arrestin1 interacts with CD74 upon MIF stimulation. A, CD74 co-localizes with b-arrestin1 upon MIF stimulation. GFP-CD74 and
ARRB1-myc-expressing COS-7 cells were stimulated with MIF (200 ng/ml) for 1 h, and stained with anti-myc antibody and TRITC-labeled secondary
antibody. The cellular distribution of b-arrestin1 and CD74 was imaged by confocal microscopy. Scale bars: 10 mm B, b-arrestin1 interacts with CD74.
COS-7 cells were co-transfected with the plasmids indicated and stimulated with MIF (200 ng/ml) for 1 h. Cell lysates were immunoprecipitated with
the antibodies indicated. Whole cell lysates (Input) and immunoprecipitates (IP) were assayed by western blot with the antibodies indicated. C, Model
for b-arrestin1 mediated sustained ERK activation induced by MIF endocytosis. Upon MIF stimulation, b-arrestin1 translocates to MIF-CD74
endosomes and binds to CD74, serving as a scaffold for recruiting downstream signal molecules, such as Raf, MEK and pERK. The sustained ERK
activation stabilized by b-arrestin1 is required for Cyclin D expression and cell cycle progression.
doi:10.1371/journal.pone.0016428.g004
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flow cytometry, RAW264.7 cells were serum-starved for 2 h
before each endocytosis assay. Cells were incubated with 1 mg/ml
MIF-TRITC for the indicated time at 37uC, washed once with
citric acid buffer (132 mM citric acid and 66 mM NaH2PO4),
three times with PBS, and then fixed with 4% paraformaldehyde
and subjected to flow cytometry analysis (FACS Calibur
TM;
Becton Dickinson).
Western Blotting
Whole cell extracts were prepared from cells after the indicated
treatments. Cells first were washed with cold PBS, and then ice-
cold RIPA buffer (containing 1 mM Na3VO4, 1 mM NaF, and a
protease inhibitor mixture (Roche)) was added. After incubation
on ice for 30 min and centrifugation at 12,000 rpm for 15 min
(4uC), the supernatant was removed, and the protein concentra-
tion was determined. Equal amounts of cellular proteins were
fractionated on SDS-PAGE gels and transferred to PVDF
membranes (Millipore). Immunoblotting was performed with
indicated antibodies.
Co-immunoprecipitation
Cells were lysed with immunoprecipitation buffer (10 mM Tris–
HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
0.2 mM Na3VO4, 1% Triton X-100 plus 0.5% NP-40) containing
protease inhibitors. 500 ml of cell lysate was incubated with 2 mgo f
appropriate antibodies for 30 min at 4uC. 15 ml of Protein A/G
bead slurry (Santa Cruz) was added for another 60 min.
Immunoprecipitates were separated by SDS-PAGE electrophore-
sis and then blotted with the antibodies indicated.
Cell cycle analysis
Cells were fixed in 70% ethanol for 24 h. After removing the
ethanol by washing with PBS, incubate cells with 100 mg/ml
RNase A (DNase-free; Sigma), and 50 mg/ml propidium iodide.
At least 1610
4 cells from each sample were analyzed for DNA
content using a BD Calibur flow cytometer. Percentages of cells in
G1, S, and G2/M phases were determined using ModFIT LT
software (Verity Software House).
Immunofluorescence
COS-7 expressing GFP-CD74 and ARRB1-myc were serum
starved, washed with PBS, fixed with 4% paraformaldehyde,
permeabilized in 0.1% Triton X-100/PBS, and then blocked with
5% bovine serum albumin in PBS for 1 h. Myc antibody was used
to probe for transient b-arrestin1 expression in COS-7 for 1 h at
room temperature. Cells were washed with PBS, and incubated
with PE-conjugated rabbit secondary antibody for 1 h at RT,
washed, then mounted with Vectashield. Immunofluorescence
images were obtained using Olympus FV500 laser scanning
confocal microscope.
Supporting Information
Table S1 Oligonucleotides Used in This Study.
(DOC)
Figure S1 Time course of MIF uptake and induced ERK
activation in RAW 264.7. (A) Uptake of MIF-TRITC in RAW
264.7 cells. Cells were pre-incubated with MIF-TRITC (1 mg/ml)
at 4uC for 30 min, then washed extensively and were incubated at
37uC for the times indicated. Cells were stained with LysoTraker
Green and Hoechst. (B) The time course of MIF-induced ERK
activation. Serum-starved RAW 264.7 cells were stimulated with
MIF (200 ng/ml) for the times indicated. The cell lysates were
separated with SDS-PAGE electrophoresis and blotted with ERK
and phospho-ERK antibodies. CPZ: chlorpromazine, MIF-
TRITC: tetramethyl rhodamine-labeled MIF.
(TIF)
Figure S2 CD74 but not other receptors contributes to
MIF endocytosis. (A) CD74 co-localizes with endocytic MIF in
RAW 264.7 cells. GFP-CD74 stably expressed RAW 264.7 cells
were stimulated with (bottom) or without (upper) MIF-TRITC
(1 mg/ml) for 60 min and imaged with confocal microscopy. (B)
Co-localization of endocytic MIF with its receptor, CD44,
CXCR2 and CXCR4. RAW264.7 cells were transiently trans-
fected either with CXCR2-GFP, CXCR4-GFP or CD44-GFP
plasmid and serum-deprived overnight before being stimulated
with 1 mg/ml of MIF-TRITC for 60 min. Cellular distribution of
MIF-TRITC and its receptors was imaged by confocal microsco-
py. Scale bars: 5 mm.
(TIF)
Figure S3 Stable knockdown of CD74 and b-arrestin1 in
RAW 264.7 cells. (A) RAW 264.7 cells were stably tranfected
with CD74 and a non-specific shRNA interference plasmid.
Whole cell extracts were subjected to Western blotting with CD74
and b-tubulin antibodies. (B) RNA interference successfully
knocked down endogenous b-arrestin1. RAW 264.7 cells were
stably transfected with a b-arrestin1-specific or non-specific RNA
interference plasmid. Cell extracts were separated by SDS-PAGE
electrophoresis and subjected to Western blotting with b-
arrestin1/2 and b-tubulin-specific antibodies.
(TIF)
Figure S4 b-arrestin1 interacts with CD74 upon MIF
stimulation. (A) b-arrestin1 is co-localized with MIF in COS-7
cells when CD74 present. COS-7 cells expressing ARRB1-GFP
and CD74-myc were either unstimulated (top) or stimulated
(bottom) with MIF-TRITC (1 mg/ml) for 60 min and subsequent-
ly fixed. Cellular distribution of b-arrestin1 and MIF-TRITC was
imaged by confocal microscopy. (B) Interaction of CD74 with b-
arrestin1 is dependent on MIF stimulation. COS-7 cells were
transiently co-transfected with ARRB1-GFP and CD74-myc
plasmids for 36 h. Transfected cells were stimulated with or
without MIF (200 ng/ml) for 1 h. The cell extracts were
immunoprecipitated and blotted with the antibodies indicated.
Cell lysates were immunoprecipitated with the antibodies
indicated. Immunoblots with the antibodies indicated were used
to analyze whole cell lysates (Input) and immunoprecipitates (IP).
ARRB1, b-arrestin1.
(TIF)
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